Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Provided By GlobeNewswire
Last update: May 9, 2024
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors
Read more at globenewswire.com
